CLINICAL IMMUNOLOGY
Elevated level of some chemokines in plasma of gastric cancer patients
Submission date: 2016-09-28
Acceptance date: 2016-10-10
Publication date: 2017-01-24
Cent Eur J Immunol 2016;41(4):358-362
KEYWORDS
ABSTRACT
Introduction: Gastric cancer is one of the most common cancer-related causes of death. This is mainly due to the lack of good noninvasive method/biomarkers suitable for early-tumour diagnosis and planning of further therapy modalities. Chemokines play an important role in cancer progression and metastasis formation. In gastric cancer patients, clinical relevance of CXCL12 and CCL5 level has been postulated.
Aim of the study: Efforts were undertaken to examine whether expanded chemokine range may be relevant for evaluation of preoperative staging of gastric cancer patients.
Material and methods: Plasma from 66 gastric cancer patients and 11 healthy controls was obtained, and CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 levels were determined by flow cytometry FlexSet system.
Results: In gastric cancer patients’ plasma an increased level of CCL2, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 was observed. In the case of CCL2, CXCL9, and CXCL10, the chemokine levels correlated with advanced (III and IV in TNM classification) disease stage. In the case of CCL4, CCL5, and CXCL8, elevated levels were observed in all cancer patients in comparison to healthy donors.
Conclusions: The accuracy of preoperative diagnosis in gastric cancer may include the monitoring of a wide range of chemokines in patients’ plasma. Increased levels of chemokines may warn that the disease is more advanced than conventional diagnostic procedures suggest.
Aim of the study: Efforts were undertaken to examine whether expanded chemokine range may be relevant for evaluation of preoperative staging of gastric cancer patients.
Material and methods: Plasma from 66 gastric cancer patients and 11 healthy controls was obtained, and CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 levels were determined by flow cytometry FlexSet system.
Results: In gastric cancer patients’ plasma an increased level of CCL2, CCL4, CCL5, CXCL8, CXCL9, and CXCL10 was observed. In the case of CCL2, CXCL9, and CXCL10, the chemokine levels correlated with advanced (III and IV in TNM classification) disease stage. In the case of CCL4, CCL5, and CXCL8, elevated levels were observed in all cancer patients in comparison to healthy donors.
Conclusions: The accuracy of preoperative diagnosis in gastric cancer may include the monitoring of a wide range of chemokines in patients’ plasma. Increased levels of chemokines may warn that the disease is more advanced than conventional diagnostic procedures suggest.
REFERENCES (25)
1.
Rossi D, Zlotnik A (2000): The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
3.
Le Y, Zhou Y, Iribarren P, Wang J (2004): Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1: 95-104.
4.
Mantovani A, Sozzani S, Locati M, et al. (2002): Macrophage polarization: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
5.
Kido S, Kitadai Y, Hattori N, et al. (2001): Interleukin 8 and vascular endothelial growth factor- prognostic factors in human gastric carcinomas? Eur J Cancer 37: 1482-1487.
6.
Strieter RM, Belperio JA, Burdick MD, et al. (2004): CXC chemokines: angiogenesis, immunoangiostasis and metastasis in lung cancer. Ann N Y Acad Sci 1028: 351-360.
7.
Zhu YM, Webster SJ, Flower D, Woll PJ (2004): Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 91: 1970-1976.
8.
Raman D, Baugher PJ, Thu YM, Richmond A (2007): Role of chemokines in tumour growth. Cancer Lett 256: 137-165.
9.
Lee HJ, Kim SW, Kim HY, et al. (2009): Chemokine receptor CXCR4 expression, function and clinical implications in gastric cancer. Int J Oncol 34: 473-480.
10.
Lee HJ, Huang SM, Kim HY, et al. (2011): Evaluation of the combined expression of chemokine SDF-1a and its receptor CXCR4 as a prognostic marker for gastric cancer. Exp Ther Med 3: 499-504.
11.
Kim HK, Song KS, Park YS, et al. (2003): Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 39: 184-191.
12.
Ahn HS, Shin YS, Park PJ, et al. (2012): Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer 106: 733-739.
13.
Baj-Krzyworzeka M, Weglarczyk K, Mytar B, et al. (2011): Tumour-derived microvesicles contain interleukin-8 and modulate production of chemokines by human monocytes. Anticancer Res 31: 1329-1335.
14.
Sugasawa H, Ichikura T, Tsujimoto H, et al. (2008): Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 97: 445-450.
15.
Setoyama T, Arima H, Hokita S, Aikou T (2007): Clinical implication of CXCL12 expression in gastric cancer (SDF-1) Ann Surg Oncol 14: 3154-3158.
16.
Soria G, Ben-Baruch A (2008): The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285.
17.
Jianghong W, Xiaowen L, Yanong W (2013): Predictive value of preoperative serum CCL2, CCL18 and VEGF for the patients with gastric cancer. BMC Clin Pathol 22: 15-19.
18.
Ohta M, Kitadai Y, Tanaka S, et al. (2003): Monocyte chemoattractant protein-1 expression correlates with macrophage infliltration and tumour vascularity in human gastric carcinomas. Int J Oncol 22: 773-778.
19.
Saito S, Kitayama J, Jin ZX, et al. (2003): Beta-chemokine, macrophage inflammatory protein-1beta (MIP-1beta), is highly expressed in diffuse type human gastric cancers. J Exp Clin Cancer Res 22: 453-459.
20.
Rajkumar T, Vijayalakshmi N, Gopal G, et al. (2010): Identification and validation of genes involved in gastric tumourigenesis. Cancer Cell Int 10: 45-57.
21.
Kuai WX, Wang Q, Yang XZ, et al. (2012): Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol 18: 979-985.
22.
Sarvaiya PJ, Guo D, Ulasov I, et al. (2013): Chemokines in tumour progression and metastasis. Oncotarget 4: 2171-2185.
23.
Kim HJ, Song DE, Lim SY, et al. (2011): Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumour-infiltrating lymphocytes. PLoS One 6: e26264.
24.
Ohtani H, Jin Z, Takegawa S, et al. (2009): Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 217: 21-31.
25.
Eck M, Schmausser B, Scheller K, et al. (2000): Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 122: 192-199.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
